Skip to main content

Primary Research · 2019

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT)

Bhatt DL, Steg PG, Miller M, et al. · New England Journal of Medicine, 2019

Key finding

Double-blind RCT (n=8,179) found high-dose EPA (4g/day) reduced ischemic events by 25% vs placebo in patients with elevated triglycerides on statins — the most convincing cardiovascular benefit data for omega-3s.

About the supplement

Omega-3 Fatty Acids

Dose · mechanism · evidence grade · safety →

Read the paper

Open on PubMed

https://pubmed.ncbi.nlm.nih.gov/30415628/

Cited in 3 guides

About this page

Formulate maintains a registry of clinical studies cited across its guides and evidence grades. This page links the study metadata to the content that cites it — one canonical entry per landmark study.

The full citation chain is public so readers can verify claims without hunting through individual guide pages. Browse all cited studies →

Note: Study summaries on this page are editorial interpretations of the research. Always consult the primary source before drawing clinical conclusions.